VLS Valneva SE

VALNEVA - Declaration of shares and voting rights: Interim status at October 4, 2022 (and information at September 30, 2022)

VALNEVA - Declaration of shares and voting rights: Interim status at October 4, 2022 (and information at September 30, 2022)

VALNEVA

Declaration of shares and voting rights

Interim status at October 4, 2022 (and information at September 30, 2022)

__________________________________________________________________________________________

  

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment A

Declaration date: October 7, 2022

  

Interim status at October 4, 2022

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



138,351,857



 



    including:
  • 138,331,343 ordinary shares with a par value of €0.15 each; and
  • 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 each
160,905,006Capital increase without preferential subscription rights (21,000,000 new ordinary shares issued)



 
October 4, 2022i160,780,684

i Management Board decisions of September 29, 2022. Clearance and settlement on October 4, 2022.

Information at September 30, 2022

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



117,351,857



 



    including:
  • 117,331,343 ordinary shares with a par value of €0.15 each; and
  • 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 each
139,905,006Sale of 1,101 shares with double voting rights



 



Double voting rights granted on 65 ordinary shares
September 7 & 12, 2022



 



September 18, 2022
139,780,684

 ___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
07/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva annonce sa participation à des conférences investisseurs

Valneva annonce sa participation à des conférences investisseurs  Lyon (France), le 2 mars 2026 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et participeront à des rendez-vous avec des investisseurs institutionnels lors de prochaines conférences aux États-Unis et en Europe. Thomas Lingelbach, directeur général, et Peter Bühler, directeur financier, feront un point sur les principaux éléments de création de valeur de la Société ainsi que les catalyseurs attendus, dont les...

 PRESS RELEASE

Valneva to Participate in Upcoming Investor Conferences

Valneva to Participate in Upcoming Investor Conferences Lyon (France), March 2, 2026 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Buhler will discuss the Company’s key value drivers and upcoming catalysts, including the topline Phase 3 data readout for VLA15, the Company’s Lyme disease vaccine candidate, which partner Pfizer expects to report in the first half of 2026. The TD Cowen presenta...

Martial Descoutures
  • Martial Descoutures

ResearchPool Subscriptions

Get the most out of your insights

Get in touch